-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Initiates Coverage On Sutro Biopharma with Overweight Rating, Announces Price Target of $56

Benzinga·05/28/2026 13:40:21
Listen to the news
Barclays analyst Lukas Shumway initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Overweight rating and announces Price Target of $56.